Biogen (NASDAQ:BIIB) and its Japanese partner Eisai’s (OTCPK:ESALF) (OTCPK:ESAIY) breakthrough Alzheimer’s therapy, Leqembi (lecanemab), is now available in China, the…
Read More »Biogen (NASDAQ:BIIB) and its Japanese partner Eisai’s (OTCPK:ESALF) (OTCPK:ESAIY) breakthrough Alzheimer’s therapy, Leqembi (lecanemab), is now available in China, the…
Read More »